Zopiclone for Adult Insomnia
Zopiclone 7.5 mg is an effective and well-tolerated hypnotic agent for treating both sleep onset and sleep maintenance insomnia in adults, with a recommended starting dose of 3.75-7.5 mg in elderly patients (≥65 years), though it is notably absent from major U.S. guidelines and is not FDA-approved in the United States.
Recommended Dosing
Standard Adult Dosing
- Optimal dose: 7.5 mg taken at bedtime 1, 2, 3
- Dose range: 3.75-15 mg, though doses above 7.5 mg increase side effects without proportional benefit 3
- The 7.5 mg dose provides the best balance between efficacy and tolerability for most patients 4, 3
Elderly Patients (≥65 years)
- Start with 3.75-7.5 mg 4
- Maximum recommended dose: 7.5 mg (do not exceed 10 mg) 4
- Lower doses are warranted due to age-related pharmacokinetic changes
Special Populations
- Hepatic impairment: Use with caution; dose adjustment may be necessary
- Renal impairment: No dose adjustment required 1
Duration of Treatment
Short-term use (≤4 weeks) is recommended based on available evidence 1, 5. While zopiclone maintained efficacy during 4-week treatment periods without tolerance 5, longer-term data are conflicting and the potential for tolerance during extended use remains unclear 1. A 6-month study exists but was conducted with eszopiclone (the S-isomer), not zopiclone itself.
Clinical Efficacy
Zopiclone demonstrates effectiveness for:
- Sleep onset: Reduces sleep latency
- Sleep maintenance: Decreases nocturnal awakenings and wake time after sleep onset
- Total sleep time: Increases overall sleep duration 1, 2, 6
The drug is comparable in efficacy to benzodiazepine hypnotics including triazolam, temazepam, nitrazepam, and flurazepam 1, 2, 5.
Safety Profile and Adverse Effects
Common Adverse Effects
- Bitter/metallic taste (most frequent complaint, occurring in ~3.6% of patients) 1
- Dry mouth
- Mild daytime sedation (less than benzodiazepines)
Advantages Over Benzodiazepines
- Minimal residual morning effects: Less impairment of psychomotor performance and mental alertness compared to flurazepam 2, 5
- Low rebound insomnia risk: Rebound insomnia after withdrawal is uncommon in short-term studies 1, 2
- Lower dependence potential: Physical dependence symptoms are rare, though isolated cases exist in patients with substance abuse history 2
Serious Concerns
In elderly patients with Alzheimer's disease, zopiclone caused intense daytime sedation and worsened agitation with wandering in some patients, leading to treatment discontinuation 7. Additionally, an 8-point reduction in digit-symbol coding test scores was observed 7, raising concerns about cognitive impact in vulnerable populations.
Cognitive and Psychomotor Effects
- Generally well-tolerated with minimal next-day impairment 2, 5
- However, in dementia patients, significant cognitive decline was noted 7
- Does not impair psychomotor coordination at therapeutic doses, unlike flurazepam 5
Contraindications and Precautions
Absolute Contraindications
- Known hypersensitivity to zopiclone
- Severe respiratory insufficiency
- Severe hepatic impairment
- Myasthenia gravis
Use with Caution In
- Elderly patients: Higher risk of falls, confusion, and cognitive impairment 8
- Patients with dementia: Risk of worsened agitation and significant cognitive decline 7
- History of substance abuse: Increased dependence risk 2
- Hepatic impairment: Reduced clearance may necessitate dose reduction
- Concurrent CNS depressants: Additive sedative effects
Important Safety Warnings
Observational data suggest associations between hypnotics (including Z-drugs) and:
- Increased fracture risk 8
- Motor vehicle accidents 8
- In older patients: 5-fold increase in memory loss/confusion, 3-fold increase in falls, 4-fold increase in morning sedation 8
- Increased all-cause mortality (though confounding cannot be excluded) 8
Administration Guidelines
- Take immediately before bedtime with at least 7-8 hours available for sleep
- Avoid with high-fat meals: Food delays absorption by ~1 hour and may reduce sleep onset efficacy
- Do not combine with alcohol or other CNS depressants
- Intermittent use preferred over nightly continuous use when clinically appropriate
Guideline Context and Limitations
Critical caveat: Zopiclone is not mentioned in the 2017 American Academy of Sleep Medicine guidelines 9 or the 2016 American College of Physicians guidelines 8, which focus on medications available in the United States. Zopiclone is not FDA-approved in the U.S., where eszopiclone (its S-isomer) is used instead. The evidence provided includes FDA labeling for eszopiclone 10, not zopiclone.
However, zopiclone is widely used internationally and was recommended by the Brazilian Sleep Association as a standard treatment option alongside zolpidem 11. A 2025 European consensus supports its use and provides deprescribing protocols 12.
Deprescribing Protocol
When discontinuing zopiclone 12:
- Gradual taper: Reduce dose by 10-25% per week
- Consider cross-tapering to CBT-I, melatonin 2 mg prolonged-release, or daridorexant
- Monitor for rebound insomnia (though risk appears low with zopiclone)
Clinical Bottom Line
For adult insomnia, zopiclone 7.5 mg at bedtime is effective and well-tolerated for short-term use (≤4 weeks), with particular advantages in minimal next-day impairment compared to benzodiazepines. Start with 3.75-7.5 mg in elderly patients and avoid exceeding 7.5 mg in this population. Exercise extreme caution in patients with dementia due to risks of cognitive decline and behavioral disturbance. Given concerns about long-term safety, tolerance, and dependence with all hypnotics 8, prioritize cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment when feasible, reserving pharmacotherapy for short-term or intermittent use.